N. Andreasen
Department of Rehabilitation
Piteå River Valley Hospital
Sweden
Name/email consistency: high
- Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., Blennow, K. Arch. Neurol. (2001)
- Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Piteå Dementia Project. Andreasen, N., Blennow, K., Sjödin, C., Winblad, B., Svärdsudd, K. Neuroepidemiology (1999)
- Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., Blennow, K. Arch. Neurol. (1999)
- Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Andreasen, N., Minthon, L., Vanmechelen, E., Vanderstichele, H., Davidsson, P., Winblad, B., Blennow, K. Neurosci. Lett. (1999)
- Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Andreasen, N., Minthon, L., Clarberg, A., Davidsson, P., Gottfries, J., Vanmechelen, E., Vanderstichele, H., Winblad, B., Blennow, K. Neurology (1999)
- Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. Andreasen, N., Vanmechelen, E., Van de Voorde, A., Davidsson, P., Hesse, C., Tarvonen, S., Räihä, I., Sourander, L., Winblad, B., Blennow, K. J. Neurol. Neurosurg. Psychiatr. (1998)
